Biolipox – Year-end report 2004

Full-year 2004

• Biolipox secure additional funding – international venture capital firms invest EUR 30 million • NLA Nasal Spray for the treatment of rhinitis shows good efficacy in phase II study • Progress in projects leads to several patent applications • Early drug development organisation further expanded • Net sales amounted to SEK 0 (0) • Results after tax amounted to a loss of SEK 96.7 million (loss: 63.3) • Earnings per share amounted to a loss of SEK 112.25 (loss: 72.46) For the complete Year-end report 2004, please visit www.biolipox.com/finansiella_rapporter.asp For further information, please contact: Torbjörn Bjerke, President & CEO, Tel: +46 70 66 19 90, e-mail: torbjorn.bjerke@biolipox.com Peter Hein, CFO, Tel: +46 8 545 28 153, Cellular phone: +46 733 70 73 43, e-mail: peter.hein@biolipox.com For fact sheets, images and illustrations, please visit www.biolipox.com/press